Peptide Characterization and Functional Stability of a Partially Hydrolyzed Whey-Based Formula over Time
| Autor: | Loraine Merminod, Lénaïck Dupuis, Alexandre Panchaud, Michael Affolter, Christine Martin-Paschoud, Tristan Bourdeau, Carine Blanchard, Sabine Lahrichi, Sophie Nutten, Rachel Adams |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
partially hydrolyzed whey-based infant formula
Protein Hydrolysates Size-exclusion chromatography Peptide atopic dermatitis risk reduction Lactoglobulins Basophil degranulation Immunoglobulin E Article Dermatitis Atopic Rats Sprague-Dawley hypoallergenic In vivo Whey mental disorders Animals Food Industry Humans TX341-641 chemistry.chemical_classification Food Formulated Chromatography Nutrition and Dietetics biology Nutrition. Foods and food supply Chemistry allergy prevention Ligand binding assay Hydrolysis Infant Hypoallergenic Allergens Milk Proteins In vitro Infant Formula peptide Molecular Weight Whey Proteins Biochemistry biology.protein Milk Hypersensitivity Peptides Food Science oral tolerance induction |
| Zdroj: | Nutrients Volume 13 Issue 9 Nutrients, Vol 13, Iss 3011, p 3011 (2021) |
| ISSN: | 2072-6643 |
| Popis: | Human clinical trials have shown that a specific partially hydrolyzed 100% whey-based infant formula (pHF-W) reduces AD risk in the first yeast of life. Meta-analyses with a specific pHF-W (pHF-W1) confirm a protective effect while other meta-analyses pooling different pHF-W show conflicting results. Here we investigated the molecular composition and functional properties of the specific pHF-W1 as well as the stability of its manufacturing process over time. This specific pHF-W1 was compared with other pHF-Ws. We used size exclusion chromatography to characterize the peptide molecular weight (MW), a rat basophil degranulation assay to assess the relative level of beta-lactoglobulin (BLG) allergenicity and a preclinical model of oral tolerance induction to test prevention of allergic sensitization. To analyze the exact peptide sequences before and after an HLA binding assay, a mass cytometry approach was used. Peptide size allergenicity and oral tolerance induction were conserved across pHF-W1 batches of production and time. The median MW of the 37 samples of pHF-W1 tested was 800 ± 400 Da. Further oral tolerance induction was observed using 10 different batches of the pHF-W1 with a mean reduction of BLG-specific IgE levels of 0.76 log (95% CI = −0.95 −0.57). When comparing pHF-W1 with three other formulas (pHF-W2 3 and 4), peptide size was not necessarily associated with allergenicity reduction in vitro nor oral tolerance induction in vivo as measured by specific IgE level (p < 0.05 for pHF-W1 and 2 and p = 0.271 and p = 0.189 for pHF-W3 and 4 respectively). Peptide composition showed a limited overlap between the formulas tested ranging from 11.7% to 24.2%. Furthermore nine regions in the BLG sequence were identified as binding HLA-DR. In conclusion, not all pHF-Ws tested have the same peptide size distribution decreased allergenicity and ability to induce oral tolerance. Specific peptides are released during the different processes used by different infant formula producers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|